Laia Crespo, PhD
Investment Manager
lcrespo@ysioscapital.com

Laia is responsible of the identification and assessment of investment and disinvestment opportunities from the scientific and business perspectives.

Prior to joining Ysios Laia assessed commercial and scientific licensing-in opportunities as part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group.

Laia developed her professional career primarily in the biotechnology cluster of Cambridge, UK, in companies such as Spirogen, Medivir and UCB-Celltech. Her activities ranged from setting up a combinatorial chemistry platform and designing and preparing enzyme inhibitors to planning and budgeting large scale processes at the laboratory level as well as outsourcing newly developed technology to contract research organizations.

Laia obtained a first degree in Chemistry at the University of Barcelona, where she also completed a Master in Science and a PhD working on the synthesis and biophysical characterization of peptides for drug delivery applications. Laia holds an MBA from Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

top